Here are six recent GLP-1 studies:
1. The use of Ozempic and Wegovy reduced healthcare costs for overweight or obese patients with heart failure or atherosclerotic cardiovascular disease, according to studies presented Nov. 3-6 at the Obesity Society’s annual Obesity Week conference.
Among 806 patients with heart failure, average annual medical costs declined $7,502, from $29,654 before treatment to $22,152 after treatment. Among 1,282 patients with atherosclerotic cardiovascular disease, the average total medical cost fell by $9,276, or from $25,233 to $15,957.
2. Stroke survivors who took GLP-1 or sodium-glucose cotransporter-2 inhibitor medications had a 74% lower risk of death than those who did not take these therapies, according to a preliminary study of 7,044 adult stroke survivors.
The results were presented at the American Heart Association’s annual Scientific Sessions in mid-November.
3. A three-year, phase 3 trial found that Eli Lilly’s Mounjaro significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults. Nearly 99% of patients who took Mounjaro remained diabetes-free by the end of the study.
4. The use of GLP-1s — Ozempic, Wegovy, Saxenda and Victoza — were associated with a reduced risk of hospitalization due to alcohol-related events, according to researchers who analyzed data from 227,886 patients diagnosed with alcohol use disorder between 2006 and 2021.
5. Compared to a placebo, patients with Type 2 diabetes who took a GLP-1 saw reduced major adverse cardiovascular events by 13%, the composite kidney outcome by 18%, kidney failure by 16% and all-cause death by 12%, on average. The study compiled GLP-1 trials that had at least 500 participants and lasted over 12 months.
6. Amgen’s experimental GLP-1 drug, MariTide, resulted in an average 20% reduction in body weight in nondiabetic adults who are obese or overweight. The 52-week, phase 2 study also investigated the weight loss results among adults with Type 2 diabetes who were obese or overweight, and found an average 17% weight loss.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
